Business
View of ocean from cruise ship railing
Getty Images
Cruisey

Virgin Voyages just launched an annual pass for $120K, as Disney plans a huge cruise expansion

Will “work from helm” ever catch on? Virgin boss Richard Branson hopes so.

Tom Jones

Just a few years ago, the cruise industry was on its knees, with some of its biggest players on the verge of bankruptcy. It’s now back and bigger than ever: Disney is planning to spend $12 billion over the next 10 years, with the maiden voyage of the 1,119-foot-long Disney Treasure later this month the first step in a plan to more than double its fleet to 13 ships by 2031, while Virgin hopes its new unlimited pass could get cruise-goers to part ways with $120,000 and join them for up to a whole year.

Around the world in 365 days

While living at sea for an entire year might sound like an anxiety dream for many of us, it’s quickly becoming a reality in cruise tourism. For the six-figure sum (plus what would presumably be a very hefty onboard bill), you and a guest can clamber aboard Virgin’s cruiseliners for up to 365 days of sailing across Europe, the Caribbean, the Mediterranean, and anywhere else covered by the travel giant’s fleet. The offer shows Virgin’s intent to kickstart the “work from helm” idea touted by chief Richard Branson earlier this year when promoting its seasonal summer passes, offering perks such as free premium Wi-Fi and 2 specialty coffees a day.

Virgin Voyages’ annual pass fits into a growing trend in the cruising industry of longer onboard stretches, with Villa Vie Residencies giving customers the chance to set sail on its “perpetual world cruise” for up to 4 years at a time.

Cruise line passenger growth
Sherwood News

With cruise passengers now exceeding pre-pandemic levels, per data from the Cruise Lines International Association, companies like Virgin and Villa Vie are picking up on the world’s growing appetite for cruises.

Interestingly, in huge news for anyone looking to celebrate Bitcoin’s recent surge, the annual pass is also the first cruise product to accept the cryptocurrency as payment — perhaps reflecting the growing number of young people taking to the sea, with 1 in 2 passengers on Royal Caribbean cruises reportedly millennials or younger.

More Business

See all Business
Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.